Navigation Links
Auxilium Pharmaceuticals, Inc. To Present At The Stifel Nicolaus Healthcare Conference
Date:9/5/2013

CHESTERBROOK, Pa., Sept. 5, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Stifel Nicolaus Healthcare Conference to be held September 11-12, 2013 at the Four Seasons Hotel in Boston.  Mr. Jim Fickenscher, Chief Financial Officer, is scheduled to present an overview of the Company and its product pipeline at 8:00 a.m. ET on Thursday, September 12, 2013.  

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

The presentation will also be webcast on the "For Investors" section of the Auxilium website under the "Events" tab on September 12, 2013. To access the live webcast, please log on to Auxilium's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.  The presentation replay will be available for ninety days after the event.About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences.  Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism in the U.S. and XIAFLEX® (collagenase clostridium histolyticum (CCH)) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Swedish Orphan Biovitrium AB has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 71 Eurasian and African countries. Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico.  Auxilium also markets TESTOPEL®, a long-acting implantable testosterone replacement therapy, Edex®, the leading branded non-oral drug for erectile dysfunction, Striant®, a buccal system for testosterone delivery, Osbon ErecAid®, the leading device for aiding erectile dysfunction, and also has a non-promoted respiratory franchise, including Theo-24® and Semprex®-D, along with three other non-promoted products, in the U.S.  Auxilium has three projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie's disease.  CCH is in phase II of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase II of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy).  Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, which discuss matters that are not facts, and may include words to indicate their uncertain nature such as "believe," "expect," anticipate," "intend," "plan," "could," "estimate," "project," "will," and "target."  Our forward-looking statements convey management's expectations, beliefs, plans and objectives regarding future performance of the Company and are based upon preliminary information and management assumptions.  No specific assurances can be given with respect to whether: Company management will present at the Morgan Stanley Conference; or  the Company will be successful in obtaining FDA approval for its product candidates.  While the Company may elect to update the forward-looking statements made in this news release in the future, the Company specifically disclaims any obligation to do so.  Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to product development, revenue, expense and earnings expectations, intellectual property rights, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration, and those risks discussed in our reports on file with the Securities and Exchange Commission (the "SEC"). Our SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of the Company's home page on the Internet at http://www.auxilium.com under the heading "For Investors - SEC Filings." There may be additional risks that the Company does not presently know or that the Company currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.AUXILIUM CONTACTS:James E. Fickenscher / CFO

Nichol Ochsner/ Senior Director, IR  Auxilium Pharmaceuticals, Inc. 

Auxilium Pharmaceuticals, Inc.  (484) 321-5900

(484) 321-5900jfickenscher@auxilium.com

nochsner@auxilium.com


'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
3. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
4. Auxilium Pharmaceuticals to Announce Second Quarter 2013 Results and Conduct Conference Call on Thursday, August 1, 2013
5. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
6. Auxilium Pharmaceuticals, Inc. To Present At The Jefferies 2013 Healthcare Conference
7. Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference
8. Auxilium Pharmaceuticals, Inc. To Present At The UBS Global Health Care Conference
9. Auxilium Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference
10. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
11. Auxilium Pharmaceuticals to Announce First Quarter 2013 Results and Conduct Conference Call on Monday, April 29, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... , May 2, 2016  While nearly three-quarters of ... can have on their health, only about half report ... to the results of a new survey announced today ... the start of National Osteoporosis Month, Hologic is raising ... affects nearly 56 million Americans. Osteoporosis is ...
(Date:5/2/2016)... SAN FRANCISCO , May 2, 2016 /PRNewswire/ ...  is expected to reach USD 11.1 billion by ... Grand View Research, Inc. Major drivers of the ... in therapeutic areas and government recommendations for periodic ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
(Date:4/29/2016)... , April 29, 2016 ... Review, H1 2016" market research report that provides ... with comparative analysis at various stages, therapeutics assessment ... of administration (RoA) and molecule type, along with ... It also reviews key players involved in the ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... 02, 2016 , ... The National Resident Matching Program® (NRMP®) ... (“the Match”), the system through which U.S. and international medical school students and ... were placed in the 2016 Match, and 29,572 were filled when the matching ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Dr. Philip ... his patients with same day treatments. In the past, many necessary dental treatments could ... work, along with multiple anesthetic shots and extra chair time. Not only could this ...
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist , ... can visit Dr. Assili to receive any dental extraction treatment for $40 off the ... June 30, 2016. With the lower price, patients can more easily afford extractions to ...
(Date:5/2/2016)... ... , ... This week Omega Institute, a premier nonprofit educational retreat center in ... Omega is offering a record 370 in-person workshops and new online learning opportunities ... interest in or need for the knowledge and skills we’ve been cultivating for nearly ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies for their ... from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results ...
Breaking Medicine News(10 mins):